Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026

Reuters

2025/08/14

<a href="https://laohu8.com/S/ANRO">Alto Neuroscience</a> Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026

Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813841679) on August 13, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559892589"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559892589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559892589?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 04:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559892589","market":"nz","top_or_hot":-1,"title":"Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANRO\">Alto Neuroscience</a> Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813841679) on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-14 04:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ANRO\">Alto Neuroscience</a> Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813841679) on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANRO","symbol_name":"Alto Neuroscience","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDLb2G0Xr:1","article_id":"2559892589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559892589","pubTimestamp":1755115930,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANRO":"Alto Neuroscience","BK4007":"制药"},"translate_title":"Alto Neuroscience宣布到2026年中期启动ALTO-207治疗难治性抑郁症的2b期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANRO":0.9},"content_text":"Alto Neuroscience Announces Initiation of Phase 2b Trial for ALTO-207 in Treatment Resistant Depression by Mid-2026\n    \n\n        Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 in patients with treatment-resistant depression by mid-2026. The decision follows promising clinical data and the robust effects of pramipexole observed in the PAX-D study, which supports the therapeutic potential of ALTO-207. Additionally, Alto anticipates reporting topline data from the ALTO-101 Phase 2 proof-of-concept trial for cognitive impairment in schizophrenia in the second half of 2025. Further results from an exploratory study involving ALTO-203 will be presented at a future medical meeting, with subsequent development steps to be determined following a comprehensive analysis of the data.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250813841679) on August 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}